Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

Já no Sudeste, o volume de chuva aumenta, com temporais isolados em São Paulo e em Minas Gerais. ⚠️Segundo os meteorologistas, as pancadas ainda devem ser fortes no oeste da Bahia ...

Clientes solicitam subsídios do programa de troca de bens de consumo na cidade de Hangzhou, Província de Zhejiang, no leste da China, em 31 de outubro de 2024. (Xinhua/Xu Yu) Beijing, 15 jan (Xinhua) ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies ... The company in September 2024 announced that it will push through with a late-stage ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...

As habilidades em inteligência artificial são cada vez mais relevantes para os interessados em subir os degraus corporativos. Segundo uma pesquisa realizada pela empresa de software Freshworks, 55% ...